PARP2
PARP2 (poly(ADP-ribose) polymerase 2) is a nuclear ADP-ribosyltransferase that catalyzes poly(ADP-ribosyl)ation in response to DNA strand breaks and functions as a key component of the cellular DNA damage response network[1][2]. Mechanistically, PARP2 participates in base excision repair (BER) and single-strand break repair, where it cooperates with DNA repair factors to promote efficient lesion processing and genome maintenance[3][4]. Beyond its canonical repair role, PARP2 contributes to chromatin-associated DNA damage signaling through the generation of branched poly(ADP-ribose) chains, a process that regulates APLF-dependent histone H3 removal and supports DNA double-strand break repair[5]. Disease-associated studies further implicate PARP2 in inflammation, carcinogenesis, cancer progression, metabolic regulation, and oxidative stress responses, highlighting its broader biological relevance beyond genome surveillance[6]. Compared with the closely related isoform PARP1, PARP2 possesses a distinct domain organization and lacks the classical N-terminal DNA-binding zinc-finger region found in PARP1, indicating partially nonredundant mechanisms of damage recognition and activation[1][7]. Recent structural analyses further demonstrate that DNA damage-induced catalytic activation of PARP2 differs mechanistically from PARP1, supporting isoform-specific regulatory features within the PARP family[8]. For experimental applications, PARP2 is frequently investigated using pharmacological PARP inhibitors, including niraparib, olaparib, rucaparib, talazoparib, and other PARP1/2-targeting compounds, which provide valuable tools for dissecting DNA repair pathways and therapeutic vulnerabilities associated with defective genome maintenance[1][9].
References:
- [1]. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PARP2 gene information.
- [2]. PARP2 gene information from NCBI.
- [3]. Schreiber V, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 2002 Jun 21;277(25):23028-36. [Content Brief]
- [4]. Sciencedirect.topics.
- [5]. Chen Q, et al. PARP2 mediates branched poly ADP-ribosylation in response to DNA damage. Nat Commun. 2018 Aug 13;9(1):3233. [Content Brief]
- [6]. Huang Y, et al. The adjuvant treatment role of ω-3 fatty acids by regulating gut microbiota positively in the acne vulgaris. J Dermatolog Treat. 2024 Dec;35(1):2299107. [Content Brief]
- [7]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
- [8]. Guo D, et al. OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth. Mol Cell. 2025 Feb 20;85(4):843-856.e6. [Content Brief]
- [9]. Du YX, et al. Experimental realization of stimulated Raman shortcut-to-adiabatic passage with cold atoms. Nat Commun. 2016 Aug 11;7:12479. [Content Brief]
All Product Categories
-
PARP2 Related Products (84)
Related Products (84)
-
Antibodies (1)
-
PARP1-IN-49
0 ImagesCat. No.: HY-179406PARP1-IN-49 is a selective PARP1 inhibitor with an IC50 of 23.56 nM and a Kd of 17.78 nM. PARP1-IN-49 shows a selectivity for PARP1 over PARP2. PARP1-IN-49 leads to the induction of DNA damage, cell cycle arrest, and apoptosis. PARP1-IN-49 also increases intracellular ROS levels and inhibits cell migration. PARP1-IN-49 can be used for the research of breast cancer and ovarian cancer.
-
TOPOI/PARP-1-IN-2
0 ImagesCat. No.: HY-169299TOPOI/PARP-1-IN-2 (compound 6c) is a dual PARP-1 and topoisomerase 1 (TOPO-1) inhibitor with IC50s of 32.2 nM and 46.2 nM, respectively. TOPOI/PARP-1-IN-2 shows a selectivity for PARP-1 over PARP-2. TOPOI/PARP-1-IN-2 disrupts the cell cycle at the S phase and induces apoptosis in NCI-60 cancer cell lines.
-
PARP1/c-Met-IN-3
0 ImagesPARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC50 of 5.4 nM against c-Met and an IC50 of 3.7 nM against PARP1. PARP1/c-Met-IN-3 inhibits PARP2 enzymatic activity with an IC50 of 4.52 nM, and shows no specificity for PARP1 and PARP2. PARP1/c-Met-IN-3 induces cell cycle arrest and apoptosis. PARP1/c-Met-IN-3 exhibits anti-tumor activity against triple-negative breast cancer.
-
PARP1-IN-44
0 ImagesCat. No.: HY-178032PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active PARP1 inhibitor (IC50 = 0.6 nM), and also inhibits PARP2 (IC50 = 1.0 nM) and PARP7 (IC50 = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy.
-
ATR/PARP1-IN-1
0 ImagesCat. No.: HY-174828ATR/PARP1-IN-1 is a potent ATR and PARP1 dual inhibitor with IC50s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change.
-
PARP1/EZH2-IN-1
0 ImagesCat. No.: HY-179386PARP1/EZH2-IN-1 is a selective PARP1 and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC50s of 28 nM, 414 nM and 74 nM for PARP1, PARP2 and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research.
-
YCH3292
0 ImagesCat. No.: HY-180809CAS No.: 3049753-10-5YCH3292, a derivative of YCH189 (HY-155993) is a potent, selective and orally active PARP1/2 inhibitor with IC50 both <0.001 nM. YCH3292 can increase the stability of PARP-DNA complexes. YCH3292 exhibits robust antiproliferative activity. YCH3292 can induce double-strand breaks in DNA, increase the protein levels of γH2AX, P-RPA32, and P-Chk1 and induce tumor cells S or G2/M phase arrest and apoptosis. YCH3292 can inhibit tumor growth in MC38 xenograft model.
-
PARP-1/2-IN-5
0 ImagesCat. No.: HY-179349CAS No.: 489457-75-2PARP-1/2-IN-5 (Compound 12) is a PARP-1/2 inhibitor, with the IC50 values for PARP-1 and PARP-2 being 118 and 11 nM respectively. PARP-1/2-IN-5 can be used for the study of inflammatory diseases and neurodegenerative disorders.
-
(rac)-Talazoparib
0 ImagesCat. No.: HY-14687CAS No.: 1207454-56-5Synonyms: (rac)-BMN-673; (rac)-LT-673(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with Ki of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC50 of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC50 of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models.
-
AZ0108
0 ImagesCat. No.: HY-100847CAS No.: 1825345-52-5AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC50s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC50 of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI50 of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models.
-
MC2050
0 ImagesCat. No.: HY-182246CAS No.: 1301757-19-6MC2050 is a selective PARP-1 inhibitor with an IC50 of 119 nM. MC2050 functionally inhibits PARP-1 activity, including hyperactivation induced by oxidative stress, and reduces the poly (ADP-ribosyl) ation level of histone H1. MC2050 protects neuroblastoma cells from oxidative stress-mediated cell death induced by hydrogen peroxide. MC2050 is applicable to research related to neuroblastoma and Burkitt lymphoma.
-
PARP1-IN-37
0 ImagesCat. No.: HY-171543CAS No.: 952474-39-4PARP1-IN-37 (Compound 8) is an orally active and selective poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor with an IC50 value of 24 nM for PARP1. PARP1-IN-37 inhibits PARP activity in cells with an EC50 value of 3.7 μM. PARP1-IN-37 is promising for research of BRCA-mutated tumors, such as breast and ovarian cancers.
-
NDs-IN-1
0 ImagesCat. No.: HY-158334CAS No.: 3033806-97-9(Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
-
PARP1-IN-34
0 ImagesCat. No.: HY-170432PARP1-IN-34 (compound 30) is a selective PARP1 inhibitor with an IC50 of 0.32 nM. PARP1-IN-34 is a subnanomolar PARP1 inhibitor with >1000-fold selectivity against PARP2 with an IC50 of 326 nM. PARP1-IN-34 shows antitumor efficacy[1].
-
PARP1 degrader-3
0 ImagesCat. No.: HY-189293PARP1 degrader-3 is a selective PARP1 degrader derived from Olaparib (HY-10162) bearing a bicyclo[1.1.1]pentane (BCP) hydrophobic tag. PARP1 degrader-3 degrades PARP1 with a DC50 of 4.31 μM. PARP1 degrader-3 induces PARP1 degradation primarily through the ubiquitin-proteasome system, and the HSP70/HSP90-associated protein quality control pathway may be involved in this process. PARP1 degrader-3 can be used for colorectal cancer-related research.
-
OUL245
0 ImagesCat. No.: HY-W294889CAS No.: 1023814-45-0
-
PARP-1/2/7-IN-1
0 ImagesCat. No.: HY-161606CAS No.: 3034665-49-8PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC50 of ＜ 10 nM.
-
PP-048
0 ImagesCat. No.: HY-189225PP-048 is a selective dual inhibitor of Polθ/PARP1, with IC50 values of 4.9 nM and 6.8 nM for the Polθ helicase/ATPase domain and PARP1, respectively. PP-048 impairs the compensatory DNA repair capacity of homologous recombination-deficient cells by simultaneously inhibiting the DNA repair functions associated with Polθ and PARP1, thereby exacerbating DNA double-strand damage and inducing apoptosis. PP-048 exhibits more potent selective antiproliferative activity against HR-deficient cancer cells. PP-048 can be used in studies related to Polθ/PARP1 dual-target inhibition, synthetic lethality, DNA damage repair, and HR-deficient triple-negative breast cancer.
-
PARP1-IN-35
0 ImagesCat. No.: HY-168851PARP1-IN-35 (compound T26) is a selective, orally active, cross -the blood-brain barrierPARP1 inhibitor with IC50 values of 0.2, 122 nM for PARP1, PARP2, respectively. PARP1-IN-35 shows antiproliferative activity and anticancer activity. PARP1-IN-35 has the potential for the research of breast cancer.
